

IN THE CLAIMS

Please amend the following claims. In accordance with 37 C.F.R. § 1.21(c)(1), a marked-up version of the claims is set forth at the end of this response under the heading "Marked-up Version of the Claims."

BS 30. A method of modulating the endogenous enzymatic activity of the tyrosine kinase MCK-10 receptor comprising the amino acid sequence of SEQ ID NO. 2 or splice variants thereof as set forth in Figure 2, in a mammal comprising administering to the mammal an effective amount of a ligand to the MCK-10 receptor protein to modulate the enzymatic activity.

Please add the following new claims:

75. The method of claim 30, wherein said ligand is an antibody.

Be 76. A method of modulating the endogenous enzymatic activity of the tyrosine kinase MCK-10 receptor comprising an amino acid sequence that is at least 80% homologous to SEQ ID NO. 2, in a mammal comprising administering to the mammal an effective amount of a ligand to the MCK-10 receptor protein to modulate the enzymatic activity.

77. The method of claim 76, wherein said ligand is an antibody.

REMARKS

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and in view of the reasons which follow.

I Status of the claims

Following entry of this amendment, claims 17, 21, 25, 30 and 75-77 are pending, while claims 17, 21, and 25 have been withdrawn from consideration. Claim 30 has been amended and claims 75-77 have been added. Support for